JP2021093995A - Composition for ameliorating obesity and composition for ameliorating type ii diabetes - Google Patents

Abstract

To provide a composition for ameliorating obesity with excellent obesity-ameliorating effect, and a composition for ameliorating type II diabetes with excellent type II diabetes-ameliorating effect.SOLUTION: A composition for ameliorating obesity and a composition for ameliorating type II diabetes of the present invention contains a thermolysin processed product of rice bran. The thermolysin processed product may contain at least one kind selected from the group selected from sequence number 1 and Leu-Arg-Ala. The thermolysin processed product is produced by processing squeezed/defatted rice bran by thermolysin, and may be water-soluble fraction.SELECTED DRAWING: None

Description

The present invention relates to a composition for improving obesity and a composition for improving type II diabetes, which contains a component derived from rice bran.

In general, rice bran is a composition obtained by gathering pericarp, seed coat, germ, etc. obtained in the process of milling brown rice, and has been used as a raw material for rice bran oil, a bran bed pickled in bran, and the like for a long time. It is also known that rice bran contains useful components such as phytic acid and ferulic acid having antitumor activity and antioxidant activity, and γ-oryzanol having climacteric disorder improving activity and ultraviolet absorbing activity. ing. Therefore, rice bran has traditionally been used as a raw material for pharmaceuticals, cosmetics, etc., in addition to highly nutritious health foods.

Further, in recent years, as disclosed in Patent Documents 1 and 2, for example, by allowing a specific protease to act on rice bran, an effect of improving an action useful for a living body such as an ACE inhibitory activity has been found.

Japanese Patent No. 6296722 Japanese Patent No. 6462100

An object of the present invention is to provide an obesity-improving composition having an excellent obesity-improving effect. Another object of the present invention is to provide a composition for improving type II diabetes, which is excellent in improving type II diabetes.

The present invention is based on the finding that a thermolysin-treated product of rice bran exerts an excellent effect of improving obesity and an effect of improving type II diabetes.
In order to achieve the above object, the composition for improving obesity according to one aspect of the present invention is characterized by containing a thermolysin-treated product of rice bran.

The thermolysin-treated product may contain at least one selected from SEQ ID NO: 1 and Leu-Arg-Ala.
The thermolysin-treated product is a thermolysin-treated product of pressed degreased rice bran and may be a water-soluble fraction.

The improvement in obesity may be a decrease in white adipose tissue.
The composition for improving type II diabetes of another aspect of the present invention is characterized by containing a thermolysin-treated product of rice bran.

The improvement in type II diabetes may be an improvement in glucose metabolism or an improvement in insulin resistance.

According to the present invention, an excellent obesity improving effect can be exhibited. Further, according to the present invention, it is possible to exert an excellent effect of improving type II diabetes.

Graph showing body weight change from 7 to 25 weeks of age in the population of each test group. The graph which shows the intake of the test meal in the population of each test group. The graph which shows the change of the blood glucose level of the population of each test group in a glucose tolerance test. The graph which shows the change of the blood glucose level of the population of each test group in an insulin tolerance test. The graph which shows the mass of white adipose tissue in the population of each test group. The graph which shows the mass of brown adipose tissue in the population of each test group. The graph which shows the mass of the liver in the population of each test group.

(First Embodiment)
Hereinafter, the first embodiment in which the composition for improving obesity of the present invention is embodied will be described. The rice bran used as a raw material for the thermolysin-treated rice bran contained in the composition for improving obesity of the present embodiment is not particularly limited, but may be, for example, rice bran itself or defatted rice bran may be applied. Examples of the defatted rice bran include squeezed defatted rice bran degreased by pressing, extracted defatted rice bran extracted using an organic solvent, and the like. Among these raw materials, squeezed defatted rice bran is preferable. Examples of the method for producing squeezed degreased rice bran include a method in which lipase is inactivated by first heating rice bran (raw rice bran) obtained after polishing (lipase inactivation treatment), and then squeezing treatment is performed.

The lipase inactivation treatment is carried out for the purpose of preventing oxidative deterioration of rice bran (raw rice bran) containing about 18 to 20% by mass of lipid. Usually, it is carried out by heating and roasting raw rice bran at about 70 to 130 ° C. As the squeezing treatment, a known squeezing method, for example, a method of squeezing rice bran that has been heat roasted to about 100 to 115 ° C. with a low temperature continuous squeezing machine (for example, a trade name: Miracle Chamber manufactured by TechnoSigma) can be applied. The squeezing is preferably carried out until the lipid content in the defatted rice bran after squeezing is about 5 to 20% by mass. Further, the drying treatment may be carried out for the purpose of reducing the water content of the rice bran before the lipase deactivation treatment and the degreased rice bran after the oil extraction. Further, it is particularly preferable that the squeezed degreased rice bran is pulverized and classified by a known method to form a powder. At this time, the average particle size of the powder is preferably 5 to 200 μm, more preferably 10 to 150 μm, and most preferably 40 to 100 μm. The average particle size can be measured by the sieving method. The lipid content in the defatted rice bran is not particularly limited, but is preferably 5 to 20% by mass, more preferably 7 to 15% by mass. As the degreased rice bran, a commercially available product may be used. Examples of commercially available products include the trade name Hi-Bleff (manufactured by Saint-Blanc).

Thermolysin is a neutral metalloproteinase derived from Bacillus thermoproteolitics and has an EC number of 3.4.24.27. As the thermolysin, one extracted and purified from the above-mentioned microorganism may be used, one biochemically synthesized may be used, or a commercially available product may be used. Examples of commercially available products include those manufactured by Peptide Institute, Ltd., Wako Pure Chemical Industries, Ltd., and the like.

The treatment conditions for obtaining the thermolysin-treated product are not particularly limited as long as the thermolysin activity can be obtained, and various conditions such as temperature, pH, and time can be appropriately set. As a treatment method, for example, water is added as a solution to the rice bran raw material, the pH is adjusted if necessary, and then a predetermined amount of thermolysin is added. The amount of thermolysin added can be appropriately set in consideration of the treatment conditions, the ratio with the raw material, the titer of the enzyme, and the like. As the rice bran raw material at the time of the thermolysin treatment, rice bran or defatted rice bran as the rice bran raw material may be applied as it is, or a water extract (water-soluble fraction) of the rice bran raw material may be applied. The water extract of the rice bran raw material is a liquid composition (composed of water and the extracted rice bran component) obtained by extracting the rice bran raw material with water. The water extraction conditions are not particularly limited, and examples thereof include a method of immersing (or stirring) the rice bran raw material in water at about 10 to 50 ° C. for about 1 to 24 hours.

As the treatment conditions for thermolysin, for example, rice bran raw material and thermolysin can be mixed with water and reacted at about 37 ° C. with gentle stirring for about 10 to 30 hours. After the treatment, the thermolysin may be inactivated. The deactivation treatment of thermolysin can be performed, for example, by heating (for example, treatment at 100 ° C. for about 10 to 20 minutes).

The thermolysin-treated product is a composition obtained by treating rice bran with thermolysin as described above, and is a composition containing a decomposition product (particularly a peptide) of a protein derived from rice bran whose molecular weight is reduced by thermolysin. Such peptides preferably include those of about 10 kDa or less. More specifically, it more preferably contains at least one selected from SEQ ID NO: 1 (Val-Tyr-Thr-Pro-Gly) and Leu-Arg-Ala.

When the treatment liquid after the thermolysin treatment contains oil, it is preferable to take out a water-soluble fraction further containing a rice bran proteolytic product. Such a water-soluble fraction contains a component that exerts an obesity-improving effect and a type II diabetes-improving effect, which will be described later. The water-soluble fraction can be obtained by, for example, centrifuging the treatment liquid after the thermolysin treatment. Further, it is preferable that the treatment liquid after the thermolysin treatment is collected as a filtrate from which the insoluble fraction has been removed by filtration.

The form of use of the thermolysin-treated rice bran is not particularly limited, and the treated solution obtained as described above may be applied as it is as a composition for improving obesity in a liquid form, or a concentrated solution concentrated by distillation or the like. It may be applied as a solid substance after being dried by freeze-drying or the like.

The obesity-improving composition containing a thermolysin-treated rice bran is applied for obesity-improving, and exhibits an excellent obesity-improving effect particularly when taken orally. Obesity refers to a state in which the body weight is heavier than in a normal state and a state in which the amount of body fat is excessively accumulated. In addition, the composition for improving obesity of the present embodiment includes not only application for improving obesity but also application for prevention or delay of exacerbation of symptoms and prevention of obesity in healthy subjects.

Mature adipocytes that make up adipose tissue in a living body are roughly classified into brown adipocytes and white adipocytes. White adipocytes are adipocytes having a function of accumulating fat, and are known to decompose fat for the purpose of supplementing the lack of energy when a state of energy shortage such as fasting occurs. On the other hand, brown adipocytes are known to oxidatively decompose fat even in a normal state. Most of the adipocytes in adults are white adipocytes, which are widely distributed as subcutaneous fat, visceral fat, etc., and accumulate excess energy in the body as fat. The composition for improving obesity of the present embodiment improves the obesity state by particularly reducing white adipocytes and reducing excess body fat such as subcutaneous fat and visceral fat.

The obesity-improving composition of the present embodiment may be used for improving, preventing or preventing various obesity-related diseases. The application of the composition for improving obesity improves obesity and is expected to have an effect of improving various diseases related to obesity. Various diseases related to obesity include, for example, diabetes, arteriosclerosis, abnormal glucose tolerance, metabolic syndrome, hypertension, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, liver disease, periodontal disease (gingeritis, Periodontitis) and the like.

The application form of the composition for improving obesity is not particularly limited, and is applied, for example, as a food or drink, a pharmaceutical product, or a quasi-drug. The thermolysin-treated product of rice bran may be used as it is as a food or drink or a pharmaceutical material, or may be used as a product after appropriately blending a carrier, an additive or the like that is acceptable in terms of pharmacy or food hygiene.

When the composition for improving obesity of the present embodiment is applied to foods and drinks such as foods and beverages, for example, food additive compositions, various confectioneries, gums, tablets, capsules (soft capsules, hard capsules), various processed foods, etc. It can be applied to various beverages. The form can be appropriately designed according to the material to be applied, and can be configured as, for example, a solid state such as powder or granule, a paste, or a liquid.

The uses of foods and drinks are not particularly limited, and are so-called general foods, health foods, functional foods, dietary supplements, supplements, foods for the sick, special-purpose foods, health functional foods, nutritional functional foods, and foods for specified health use. , Applicable as functional foods. Further, it may be applied as a diet food, a beauty food, a food for exercise therapy, and an obesity treatment food. When a label of use is attached to food and drink, the label stipulated by various laws, enforcement regulations, guidelines, etc. can be mentioned. In the case of food and drink, the indication of use includes not only the indication on packages such as packaging and containers, but also the indication on advertising media such as pamphlets. In addition to displaying the improvement, prevention, prevention of exacerbation, or delay of symptoms of obesity, the display contents of the use of the composition for obesity improvement of the present embodiment include improvement, prevention, and exacerbation of various obesity-related diseases described above. Prevention of obesity, or indication of delayed symptoms. It also includes indications suggesting these improvements, preventions, prevention of exacerbations, or delays in symptoms. For example, reduction, suppression of decrease or increase of fat such as body fat, body fat percentage, blood neutral fat, subcutaneous fat, abdominal fat, visceral fat, weight loss, suppression of decrease or increase, body mass index (BMI) ) Decrease, improve BMI value higher, improve body shape, help reduce waist circumference, and so on.

When the composition for improving obesity of the present embodiment is used as a drug or a quasi-drug, it can be administered by intestinal administration or the like in addition to the case of administration by ingestion (oral ingestion). The dosage form is not particularly limited, but may be configured as, for example, a powder, a powder, a granule, a tablet, a capsule, a pill, a suppository, a liquid, or the like. Further, excipients, bases, emulsifiers, solvents, stabilizers and the like may be blended as additives.

The action and effect of the obesity-improving composition of the present embodiment will be described.
(1) Generally, a state in which the body weight is heavier than in a normal state or a state in which body fat is excessively accumulated is called obesity. Recently, obesity can be quantitatively grasped using BMI as an index. There are various causes of obesity, but it is often caused by lifestyle-related habits such as high-calorie diet, drinking / smoking, lack of exercise, and stress. Obesity is known as a risk factor for arteriosclerosis, which is a cause of adult diseases such as myocardial infarction and cerebral infarction, and has become a serious social problem. At present, no fundamental treatment method has been established for the symptoms of obesity other than improvement of eating habits and moderate exercise. Since people with obesity have a higher risk of developing myocardial infarction and cerebral infarction than healthy people, there is an urgent need to develop a composition for preventing obesity and a composition for improving obesity.

The composition for improving obesity of the present embodiment was configured to contain a thermolysin-treated product of rice bran. Since it is a naturally derived component, it can be safely applied to the living body and can exert an excellent effect of improving obesity.

(Second Embodiment)
Hereinafter, a second embodiment in which the composition for improving type II diabetes of the present invention is embodied will be described. Hereinafter, the differences from the first embodiment will be mainly described. The thermolysin-treated rice bran used in the composition for improving type II diabetes of the present embodiment is the same as that of the first embodiment.

The composition for improving type II diabetes of the present embodiment is applied for improving type II diabetes, and exhibits an excellent type II diabetes improving effect particularly when taken orally. In particular, it improves the symptoms of type II diabetes by improving glucose metabolism or insulin resistance. Type II diabetes is a disease in which the blood glucose level and the hemoglobin A1c level exceed a predetermined standard, but in the present embodiment, the blood glucose level and the hemoglobin A1c level are higher than the normal values, for example, so-called. The diabetic reserve group shall also be included. Improvement of glucose metabolism means, for example, improvement of blood glucose level and hemoglobin A1c (HA1c) level. In addition, the composition for improving type II diabetes of the present embodiment is not only applied to patients for the purpose of improving symptoms related to improvement of type II diabetes, but also prevents or delays exacerbation of symptoms, and causes type II diabetes in healthy subjects. It shall also include application for the purpose of prevention.

The composition for improving type II diabetes of the present embodiment may be used for improving, preventing or preventing various complications of diabetes associated with type II diabetes. The application of the composition for improving type II diabetes improves diabetes and is expected to have an effect of improving complications. Examples of diabetic complications include diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy.

The application form of the composition for improving type II diabetes is the same as that of the first embodiment. When applied to foods and drinks, the indications for the use of the composition for improving type II diabetes include the indication of improvement, prevention, prevention of exacerbation of type II diabetes, or delay of symptoms, as well as the above-mentioned complications. Improvement, prevention, prevention of exacerbation, or indication of delayed symptoms. It also includes indications suggesting these improvements, preventions, prevention of exacerbations, or delays in symptoms. For example, there are expressions such as improvement of blood glucose level or HA1c level, prevention of deterioration, gradual rise of blood glucose level after meal, and those who are concerned about blood glucose level.

The action and effect of the type II diabetes improving composition of the present embodiment will be described.
(2) The composition for improving type II diabetes of the present embodiment was configured to contain a thermolysin-treated product of rice bran. Since it is a naturally derived component, it can be safely applied to a living body and can exert an excellent effect of improving type II diabetes.

The above embodiment can be modified as follows. The above embodiment and the following modified examples can be implemented in combination with each other within a technically consistent range.
-The composition for improving obesity or the composition for improving type II diabetes of the above-described embodiment may be applied to domestic animals other than humans.

-In the composition for improving obesity or the composition for improving type II diabetes of the above-described embodiment, the amount of the thermolysin-treated rice bran contained in the drug, quasi-drug, or food or drink is as long as the effect of the present invention can be obtained. It is not particularly limited, and can be configured to contain, for example, 0.1 to 100% by mass, preferably 1 to 90% by mass in the solid content. In addition, the daily intake and the intake period can be appropriately set according to the purpose, condition, and the like.

-When prepared using pressed defatted rice bran as a raw material in the thermolysin-treated rice bran blended in the composition for improving obesity or the composition for improving type II diabetes of the above embodiment, γ-, which is an oily component in the rice bran raw material, is used. Oryzanol may be prepared, for example, in an amount of 50 mg / 100 g (solid content) or less, preferably 25 mg / 100 g (solid content) or less.

Hereinafter, the above-described embodiment will be described in more detail with reference to test examples, but the present invention is not limited thereto.
<Test Example 1: Improvement of obesity and type II diabetes>
(Preparation of thermolysin-treated rice bran)
As the raw material rice bran, the trade name Hibref manufactured by Saint-Blanc was used. Hybref is a squeezed degreased rice bran that has been degreased by squeezing the rice bran. As the thermolysin, one manufactured by Peptide Institute (Code3504) was used.

First, the rice bran raw material was mixed with ultrapure water so as to be 30 g / L, and thermolysin was added to this so as to be 0.4 g / L. Then, the mixture was enzymatically treated in a 37 ° C. incubator using a stirrer while stirring at 250 r.p.m. for 20 hours. Next, it was immersed in a boiling water bath and treated for 15 minutes to inactivate the enzyme. Then, the mixture was centrifuged at 7150 r.p.m. (8000 × g) for 15 minutes at 15 ° C. to perform solid-liquid separation. The pH of the obtained supernatant was adjusted to 7.0 using NaOH, and the filter paper No. Filtration was carried out using 2 (manufactured by Advantech), and the obtained filtrate was lyophilized. The freeze-dried product was used as a rice bran thermolysin-treated product. It has been confirmed by ultrafiltration that the rice bran thermolysin-treated product contains a peptide of about 10 kDa or less. In addition, it has been confirmed by amino acid sequence analysis that the peptides of SEQ ID NO: 1 and Leu-Arg-Ala are contained.

(Mouse and feed)
An in vivo test was performed using mice. As the mouse, NSY mouse (manufactured by Hoshino Test Animal Breeding Co., Ltd.), which is a spontaneous type II diabetic mouse, was used. NSY mice are characterized by mild obesity, visceral fat accumulation, and insulin resistance.

As a test diet, HFD-60 (manufactured by Oriental Yeast Co., Ltd.) consisting of the components shown in Table 1 below was used as a high-fat diet. As the high-fat diet containing the rice bran thermolysin-treated product, a high-fat diet containing 0.04% by mass of the above-mentioned rice bran thermolysin-treated product was prepared based on the composition of HFD-60 as shown in Table 1.

The content of γ-oryzanol was measured by HPLC for each of the rice bran thermolysin-treated product blended in the high-fat diet and the pressed defatted rice bran (Hybref) used as the raw material rice bran. The results are shown in Table 2.

（飼育条件及び飼料の投与）
まず、通常食（CE-2固形）にて予備飼育後、４週齢となったマウスに高脂肪食（HFD-60）のみを３週間与えた。７週齢となったマウスの体重を測定し、各群の体重の平均値の有意差がなくなるように、高脂肪食のみで飼育するコントロール群（ｎ＝８）と、米糠サーモリシン処理物配合の高脂肪食を与える実施例群（ｎ＝８）の２群に分けた。その後、コントロール群は、２６週齢まで高脂肪食のみを与えた。一方、実施例群においては、７週齢から２６週齢まで米糠サーモリシン処理物配合の高脂肪食を与えた。尚、飼育中は自由摂食・自由引飲水とし、飼育環境は１２時間明期／１２時間暗期であった。飼育期間中は１週間ごとに体重を測定し、餌補充時に適宜摂餌量も測定した。また、後述する糖負荷試験においては、別途個体群を用意し、糖負荷試験欄に記載される週齢のマウスを同様の方法にて飼育した。

(Breeding conditions and feed administration)
First, after pre-rearing on a normal diet (CE-2 solid), mice aged 4 weeks were fed only a high-fat diet (HFD-60) for 3 weeks. Weigh the 7-week-old mice and mix them with a control group (n = 8) that is bred only on a high-fat diet and a rice bran thermolysin-treated product so that there is no significant difference in the average body weight of each group. It was divided into two groups, an example group (n = 8) on which a high-fat diet was given. The control group was then fed only a high-fat diet until 26 weeks of age. On the other hand, in the example group, a high-fat diet containing a rice bran thermolysin-treated product was fed from 7 to 26 weeks of age. During breeding, free feeding and free drinking were used, and the breeding environment was 12 hours light period / 12 hours dark period. During the breeding period, the body weight was measured weekly, and the amount of food intake was also measured as appropriate when supplementing food. Further, in the glucose tolerance test described later, a separate population was prepared, and the week-aged mice described in the glucose tolerance test column were bred by the same method.

Body weight changes were measured from 7 to 25 weeks of age in each test group. Mean ± standard error was calculated for the population of each test group. The results are shown in FIG. In the figure, * indicates p <0.05, and § indicates p <0.1 (t test).

In addition, the average value of the intake (g / day) of the test meal was calculated from 7 to 25 weeks of age in each test group. Mean ± standard error was calculated for the population of each test group. The results are shown in FIG.
(Glucose tolerance test)
The glucose tolerance test was performed by the ipGTT method. First, after fasting overnight (15 hours) of mice (n = 10-11) of each population aged 8 to 12 weeks, the tail of the animal is punctured and the blood glucose level is measured using a simple blood glucose level measuring device. (Fasting blood glucose level). After measuring the fasting blood glucose level, 2 g / kg BW glucose was intraperitoneally administered. At predetermined time intervals after intraperitoneal administration of glucose, the tail was punctured in the same manner as in the fasting blood glucose level measurement, and the blood glucose level was measured using a simple blood glucose level measuring device. The mean ± standard error of blood glucose level was calculated in the population of each test group. The results are shown in FIG. Note that * in the figure indicates p <0.05 (t-test).

(Insulin tolerance test)
The insulin tolerance test was performed by the ITT method. First, mice of each population (n = 6-7) 26 weeks old were fasted overnight (15 hours), the tails of the animals were punctured, and the blood glucose level was measured using a simple blood glucose level measuring device (a simple blood glucose level measuring device). Fasting blood glucose level). After measuring the fasting blood glucose level, 0.5 U / kg insulin was intraperitoneally administered. At predetermined time intervals after intraperitoneal administration of insulin, the tail was punctured in the same manner as in the fasting blood glucose level measurement, and the blood glucose level was measured using a simple blood glucose level measuring device. Assuming that the blood glucose level at the start of measurement was 100 in the population of each test group, the average value ± standard error of the blood glucose level was calculated. The results are shown in FIG. Note that * in the figure indicates p <0.05 (t-test).

(Mass measurement of adipose tissue, etc.)
After completion of the above test, blood was collected from the fundus under anesthesia with sevofluene, and then the liver, white adipose tissue, and brown adipose tissue were excised and weighed (g). Mean ± standard error was calculated for the population of each test group. The weights of the liver, white adipose tissue, and brown adipose tissue of the control group and the example group are shown in FIGS. 5 to 7, respectively. * In the figure indicates p <0.05 (t-test).

(result)
As shown in FIG. 1, it was found that the rate of body weight gain at each week was significantly suppressed in the example group in which the rice bran thermolysin-treated product was added to the high-fat diet as compared with the control group.

As shown in FIG. 5, it was found that the mass of white adipose tissue was significantly reduced in the example group in which the rice bran thermolysin-treated product was added to the high-fat diet as compared with the control group.
In other words, ingestion of the rice bran thermolysin-treated product was found to have an obesity-improving effect. As shown in FIG. 2, there was no difference in the intake of the test meal between the control group and the example group.

As shown in FIG. 3, in the glucose tolerance test, it was found that the increase in blood glucose level was significantly suppressed in the example group in which the rice bran thermolysin-treated product was added to the high-fat diet as compared with the control group.

As shown in FIG. 4, in the insulin tolerance test, the blood glucose level did not decrease even when the insulin load was as strong as 0.5 U / kg as in the control group, whereas the rice bran thermolysin-treated product was high in fat. The blood glucose level was significantly reduced in the example group added to the diet. In addition to the obesity-improving effect, the rice bran thermolysin-treated product was also found to have a type II diabetes-improving effect by improving glucose metabolism and insulin resistance.

As shown in Table 2, the rice bran thermolysin-treated product has a significantly lower content of γ-oryzanol than the pressed defatted rice bran, so that the obesity-improving action and the type II diabetes-improving action are components other than fat-soluble components. Involvement was suggested.

<Prescription example>
An example of prescription using a rice bran thermolysin-treated product is shown below.
(Prescription example 1: Tablet)
Rice bran thermolysin treated product: 10% by mass
Excipients (crystalline cellulose, etc.): 90% by mass
(100% by mass in total)
(Prescription example 2: Beverage)
Rice bran thermolysin treated product: 10% by mass
Juice: 30% by mass
Water: 60% by mass
(100% by mass in total)

Claims (6)

A composition for improving obesity containing a thermolysin-treated product of rice bran. The composition for improving obesity according to claim 1, wherein the thermolysin-treated product contains at least one selected from SEQ ID NO: 1 and Leu-Arg-Ala. The composition for improving obesity according to claim 1 or 2, wherein the thermolysin-treated product is a thermolysin-treated pressed degreased rice bran and is a water-soluble fraction. The composition for improving obesity according to any one of claims 1 to 3, wherein the improvement in obesity is a reduction in white adipose tissue. A composition for improving type II diabetes, which comprises a thermolysin-treated product of rice bran. The composition for improving type II diabetes according to claim 5, wherein the improvement of type II diabetes is an improvement of glucose metabolism or an improvement of insulin resistance.

Images